1. Introduction {#sec1}
===============

Transthyretin, also known as prealbumin, is mainly synthesized by the hepatocyte and less likely caused by hepatic disease compared to other serum proteins \[[@B1], [@B2]\]. Transthyretin has a relatively short half-life with a high percentage of essential amino acids \[[@B3]\]. Serum transthyretin has been found related to several cases of malnutrition. It is the earliest laboratory indicator that is used to evaluate nutritional status \[[@B4], [@B5]\]. In addition, transthyretin is correlated with clinical outcomes in various diseases \[[@B6]--[@B8]\]. Recently, several studies reported that transthyretin might be a useful prognostic tumor marker \[[@B9], [@B10]\]. A high level of serum albumin is found with shorter survival rates in glioblastoma patients \[[@B9]\]. The pretreatment transthyretin level is seen to be an independent prognostic indicator among patients with metastatic renal cell carcinoma \[[@B10]\]. However, the prognostic significance of pretreatment transthyretin in patients with digestive cancer is inconsistent \[[@B11]--[@B14]\]. Some studies suggested that pretreatment transthyretin is significantly linked to the prognosis of patients with gastrointestinal (GI) cancers, but some have failed to get similar results. For example, serum transthyretin is found to be a significant independent factor for overall survival (OS) in the intrahepatic cholangiocarcinoma and hepatocellular carcinoma \[[@B11], [@B12]\]. However, no significant connection is established between the transthyretin level and OS among patients with gastric cancer \[[@B14]\]. Thus, to clarify the predictive value of this potential digestive cancer biomarker, a systematic review and meta-analysis are conducted to evaluate the relationships between transthyretin and prognosis in the digestive cancers.

2. Material and Methods {#sec2}
=======================

2.1. Search Strategy {#sec2.1}
--------------------

A systematic literature search of PubMed, Embase, and Web of Science (up to November 1, 2018) was carried out by combining all related terms such as "transthyretin or transthyretin" and "tumor or cancer or carcinoma" and "survival or prognosis or outcome." The articles published in the English language were selected, and we also manually searched for the relevant studies in the references of eligible publications.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria included the following: (1) All patients were pathologically shown as primary GI cancers. (2) The correlation between pretreatment serum transthyretin and OS or recurrence-free survival (RFS) or progression-free survival (PFS) was analyzed. (3) Other related cases were classified into low and high transthyretin level groups. (4) The cut-off value for the high transthyretin level was provided.

The exclusion criteria were the following: (1) studies that focused on the relationship between transthyretin and cancers from the nondigestive system; (2) no available usable data of the hazard ratios (HRs) and 95% confidence intervals (CIs); (3) authors\' usage of abstracts, reviews, letters, editorials, and case reports; (4) related overlapping or duplicate studies.

2.3. Data Extraction {#sec2.3}
--------------------

Data separately extracted by two authors from each study included the following: the full name of the first author, the publication year, country, and type of study, along with time, total number of recruited cases, age distribution, number of males, clinical stages, cut-off selection, cut-off value, treatment methods, follow-up time, and the outcomes of OS and RFS/PFS. HRs and 95% CIs were directly selected from the multivariate or univariate analysis. The HR \> 1 indicated worse OS or RFS/PFS for the patients with low serum transthyretin. A quality assessment method was used from a study by Lin et al. \[[@B15]\] in the meta-analysis. This scale had a total of nine items on the methodology with a final score ranging from 0 (lowest) to 9 (highest).

2.4. Statistical Analysis {#sec2.4}
-------------------------

All data analyses were held using the STATA/SE 14.1. Synthesized HRs and 95% CIs were used to assess the relation of pretreatment serum transthyretin with OS and RFS/PFS. In addition, the prognostic values of serum transthyretin in GI cancers were further assessed by conducting subgroup evaluation. Chi-square-based *Q* and *I* ^2^ tests were used to evaluate the heterogeneity among related studies. The heterogeneity was considered significant if *I* ^2^ \> 50% or *P* \< 0.01, then the random effects model was employed. Otherwise, the fixed effects model was selected. To test the stability of the combined results, sensitivity analysis was conducted by evaluating each study carefully. Potential publication bias was assessed using Begg\'s plots and tests.

3. Results {#sec3}
==========

3.1. Study Selection and Characteristics {#sec3.1}
----------------------------------------

Literature retrieval strategies are seen in [Figure 1](#fig1){ref-type="fig"}. Finally, a total of 11 full-text articles in English were included \[[@B11]--[@B14], [@B16]--[@B22]\]. They all reported the connection between pretreatment transthyretin and survival outcomes in digestive cancers. The enrolled studies were carried out in China (*n* = 6), Japan (*n* = 4), and Romania (*n* = 1). The median population size was 110 (range: 25-1483). Five types of digestive cancers were analyzed, including adenocarcinoma of the esophagogastric junction (AEG), gastric cancer (GC), colorectal cancer (CRC), intrahepatic cholangiocarcinoma (ICC), and hepatocellular carcinoma (HCC). All cohort studies identified the relevance between pretreatment serum transthyretin and OS. Three studies focused on RFS. One study explored the relationship between the transthyretin level and PFS. The cut-off values for a high level of transthyretin varied from 114 mg/L to 400 mg/L while the cut-off values were mainly determined by the receiver operating characteristic (ROC) curves. The results of the quality assessment are shown in [Figure 2](#fig2){ref-type="fig"} with a median score of 7 (ranges from 5 to 9, [Table S1](#supplementary-material-1){ref-type="supplementary-material"}). The summary characteristics of eligible studies are detailed in [Table 1](#tab1){ref-type="table"}.

4. Results of the Meta-Analysis {#sec4}
===============================

4.1. Transthyretin and OS {#sec4.1}
-------------------------

A total of 11 eligible studies were evaluated to identify the relationship between pretreatment serum transthyretin and OS of digestive cancers using HR data. In [Figure 3](#fig3){ref-type="fig"}, compared with patients in the high transthyretin group, the cases with a low transthyretin level had a worse OS, with a combined HR of 1.71 (95% CI: 1.37--2.05) in the random effects model (*P* = 0.003; *I* ^2^ = 62.3%). Also, an essential prognostic significance of transthyretin was highlighted in ICC (HR = 1.76, 95% CI: 1.02--2.51) in the random effects model (*P* = 0.090; *I* ^2^ = 65.1%), AEG (HR = 2.26, 95% CI: 1.60--2.91) in the fixed effects model (*P* = 0.683; *I* ^2^ = 0.0%), and HCC (HR = 1.48, 95% CI: 1.25--1.71) in the fixed effects model (*P* = 0.301; *I* ^2^ = 18.0%), but not in GC (HR = 1.10, 95% CI: 0.89--1.31) in the fixed effects model (*P* = 0.268; *s*).

4.2. Subgroup Analysis of OS {#sec4.2}
----------------------------

The significance of pretreatment serum transthyretin was further evaluated using subgroup analysis based on the disease type, treatment, cut-off value, clinical stage, follow-up, and analysis type ([Table 2](#tab2){ref-type="table"}). A vital correlation was shown between the low transthyretin level and shorter OS for GI tract cancers (HR = 1.92, 95% CI: 1.11-2.73) and non-GI tract cancers (HR = 1.62, 95% CI: 1.29-1.96). Obviously, a decreased transthyretin was related to worse OS both in nonmetastatic patients and in mixed cases, with a combined HR estimate of 1.45 (95% CI: 1.22-1.68) and 1.97 (95% CI: 1.54-2.39), respectively. Furthermore, the low transthyretin level was notably associated with inferior OS in the subgroup with long-term follow-ups (≥5 years) (HR = 1.98, 95% CI: 1.46-2.49) and the patients treated with surgery (HR = 1.78, 95% CI: 1.45-2.12). Other subgroups stratified by cut-off value and analysis type also showed significant correlations between the pretreatment transthyretin level and OS in digestive cancers.

4.3. Transthyretin and RFS/PFS {#sec4.3}
------------------------------

Four cohort studies identified the HRs for the connection between the transthyretin level and RFS/PFS in the digestive cancers. In [Figure 4](#fig4){ref-type="fig"}, the patients with the low serum transthyretin level had a worse RFS/PFS compared to patients in the high serum transthyretin group (HR = 1.66, 95% CI: 1.14-2.18). The pretreatment decreased serum transthyretin, indicating a poor factor of RFS/PFS among patients with digestive cancers.

4.4. Publication Bias {#sec4.4}
---------------------

Begg\'s funnel plots are shown in [Figure 5](#fig5){ref-type="fig"} while the *P* values in Begg\'s tests were higher than 0.05, indicating no significant publication bias was found among the studies.

4.5. Sensitivity Analysis {#sec4.5}
-------------------------

Sensitivity analysis was seen to have no clear variation in the overall HRs. The results were reliable and robust ([Figure 6](#fig6){ref-type="fig"}).

5. Discussion {#sec5}
=============

Recently, many gastrointestinal tumor biomarkers are reported. However, some of them are confined to the tumor tissues \[[@B23]--[@B26]\]. Because the acquisition of the tumor tissue is invasive and quite hard to identify, this limits the application of these markers in the clinical practice. GI cancers, one of the most common and malignant tumors, often lead to poor prognosis \[[@B27]--[@B29]\]. The noninvasive, easily accessible factors are more conducive to risk stratification and prognosis assessment, which are useful for implementing an individualized treatment. Transthyretin is a protein that can be easily identified in the blood, inexpensive, and noninvasive. Also, it has attracted much attention for its stability and sensitivity \[[@B3], [@B30], [@B31]\]. At the same time, transthyretin is considered a good marker in assessing the patients\' nutritional status. It has a much shorter half-life (2--3 days) and can be unaffected by hydration status \[[@B32]--[@B34]\]. However, some studies are against the use of transthyretin levels as nutrition markers and patients\' outcomes \[[@B35]--[@B37]\]. For some treatments and pathological states, such as corticosteroid therapy, renal dysfunction, infection, physiological stress, and liver dysfunction, they can increase or decrease transthyretin levels \[[@B32]\]. Recently, more clinical studies also showed that serum transthyretin is related to patient prognosis in GI cancer and might serve as a promising novel prognosticator \[[@B20]--[@B22]\].

To the best of our knowledge, this meta-analysis for the first time systematically clarified the prognostic value of pretreatment serum transthyretin in patients with digestive cancer. In this paper, a pooled HR of 1.71 was taken with the corresponding 95% CI (1.37--2.05) for OS when all the currently available data were combined. The results indicated that low transthyretin was associated with a poor OS for digestive cancer. The predictive role of serum transthyretin was also seen in the specific types of digestive cancer, including ICC, AEG, and HCC. Furthermore, the subgroup analyses for OS were carried out. It was found that decreased transthyretin was an unfavorable indicator for both GI tract cancer and non-GI tract cancer. Also, it showed that a low transthyretin level was connected with shorter OS among the patients after surgery or several cases in the nonmetastatic stage or all stages. Meanwhile, the low transthyretin level might have bad effects on the long-term survival of digestive cancer patients. Similar results were also seen in the other two subgroup analyses through the cut-off value and analysis type. Additionally, decreased transthyretin was significantly correlated with inferior RFS/PFS in the digestive cancers (HR = 1.66, 95% CI: 1.14-2.18). Therefore, the pretreatment serum transthyretin might act as a useful prognostic marker that can be used to estimate the survival outcomes of the digestive cancers.

However, the results based on the analysis should be interpreted cautiously since there were several existing limitations. First, there was significant heterogeneity among the related studies. Although the random effects model was used with the pooled data, heterogeneity could be explained by the differences in the clinical pathological factors, such as age, tumor type, and disease stage. Second, several HRs and 95% CI were available in the univariate analysis but not in the multivariate analysis. Third, this meta-analysis only included published English studies. Fourth, the number of selected studies and enrolled cases was relatively limited while more studies with different populations are needed in the future. Finally, there was no consensus regarding the definition of the cut-off value for decreased serum transthyretin in the selected studies. A definitive cut-off value is highly recommended.

In summary, the study provided strong evidence that decreased pretreatment transthyretin was significantly related to poor clinical outcomes among patients with digestive cancers. Transthyretin could be used in clinical practice as a widely accepted, stable, and inexpensive nutritional indicator to evaluate the prognosis of digestive cancers. However, considering the limitations cited above, more well-designed and multicenter clinical studies should be conducted to further validate the predictive value of transthyretin in digestive cancer.
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###### 

Table S1: quality assessment of 11 studies included in the meta-analysis.

###### 

Click here for additional data file.

![Flow diagram of literature selection.](DM2019-7142065.001){#fig1}
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![The prognostic value of the low pretreatment serum transthyretin level on OS in digestive cancers.](DM2019-7142065.003){#fig3}

![Pooled HR for the association between the transthyretin level and RFS/PFS.](DM2019-7142065.004){#fig4}

![Publication bias assessment regarding OS (a) and RFS/PFS (b).](DM2019-7142065.005){#fig5}

![Sensitivity analysis of the OS (a) and RFS/PFS (b).](DM2019-7142065.006){#fig6}

###### 

Main characteristics of all included cohort studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study         Year   Cancer type   Country   Study type   Included time           Total sample   Age           No. of males (%)   Stage           Cut-off selection   Cut-off value   Treatment methods   Follow-up   End points (analysis type)
  ------------- ------ ------------- --------- ------------ ----------------------- -------------- ------------- ------------------ --------------- ------------------- --------------- ------------------- ----------- ----------------------------
  Zhou H        2015   ICC           China     R            2005-2009               370            NA            236 (63.8%)        Mixed           NA                  170 mg/L        With surgery        \<5 years   OS (M)

  Mizuguchi T   2009   HCC           Japan     R            2001-2005               100            NA            76                 Mixed           ROC                 150 mg/L        With surgery        ≥5 years    OS (U)

  Han WX        2016   AEG           China     R            January and July 2010   101            Mean 65       80 (79.2%)         Mixed           ROC                 200 mg/L        With surgery        ≥5 years    OS (M)

  Gonda K       2017   GC            Japan     R            2013-2015               110            Median 66.2   56 (50.9%)         Metastatic      NA                  180 mg/L        No surgery          \<5 years   OS (M)

  Chereches G   2017   CRC           Romania   P            2012-2015               72             Median 60     58.3%              Metastatic      NA                  400 mg/L        No surgery          \<5 years   OS (U), PFS(U)

  Zhang L       2017   AEG           China     R            2010.10-2011            355            Median 64     281 (79.2%)        Mixed           ROC                 208.33 mg/L     With surgery        ≥5 years    OS (M)

  Huang XT      2018   ICC           China     R            2006-2017               276            Median 58     147 (53.3%)        Mixed           ROC                 184 mg/L        With surgery        ≥5 years    OS (U), RFS (U)

  Li JD         2018   HCC           China     R            2001-2014               1483           Mean 51       1317 (89%)         No metastatic   NA                  170 mg/L        With surgery        ≥5 years    OS(M), RFS(M)

  Shimura T     2018   GC            Japan     R            2011-2013               30             NA            21 (70%)           Mixed           ROC                 228 mg/L        With surgery        ≥5 years    OS (M)

  Shimura T     2018   HCC           Japan     R            2011-2013               25             Mean 69.6     22 (88%)           No metastatic   ROC                 114 mg/L        With surgery        ≥5 years    OS (M)

  Zhang L       2018   HCC           China     R            2011-2013               230            Mean 51.60    193\               Mixed           ROC                 152.5 mg/L      With surgery        \<5 years   OS (M), RFS (U)
                                                                                                                 (83.90%)                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

P: prospective; R: retrospectively; ICC: intrahepatic cholangiocarcinoma; AEG adenocarcinoma of esophagogastric junction; GC: gastric cancer; CRC: colorectal cancer; HCC: hepatocellular carcinoma; OS: overall survival; RFS: recurrence-free survival; PFS: progression-free survival; ROC: receiver operating characteristic; U: univariate analysis; M: multivariate analysis: NA: not available.

###### 

Stratified analysis of pooled HRs for digestive cancer patients with lower transthyretin.

  Subgroup factor       Divided standard   No. of studies     Pooled HR (95% CI)   *P* value   Heterogeneity   
  --------------------- ------------------ ------------------ -------------------- ----------- --------------- -------
  Cancer type           GI tract cancer    5                  1.92 (1.11-2.73)     \<0.001     74.1            0.004
  Non-GI tract cancer   6                  1.62 (1.29-1.96)   \<0.001              28.2        0.223           
                                                                                                               
  Cut-off value         \<180 mg/L         5                  1.47 (1.27-1.68)     \<0.001     0.0             0.451
  ≥180 mg/L             6                  1.98 (1.26-2.69)   \<0.001              76.4        0.001           
                                                                                                               
  Treatment             No surgery         2                  1.62 (0.29-2.96)     NS          74.6            0.047
  With surgery          9                  1.78 (1.45-2.12)   \<0.001              33.4        0.150           
                                                                                                               
  Analysis type         UVA                3                  2.35 (1.68-3.02)     \<0.001     0.0             0.607
  MVA                   8                  1.53 (1.21-1.85)   \<0.001              58.8        0.018           
                                                                                                               
  Follow-up             \<5 years          4                  1.46 (0.97-1.95)     NS          61.3            0.052
  ≥5 years              7                  1.98 (1.46-2.49)   \<0.001              43.9        0.098           
                                                                                                               
  Clinical stage        Nonmetastatic      2                  1.45 (1.22-1.68)     \<0.001     0.0             0.503
  Metastatic            2                  1.62 (0.29-2.96)   NS                   74.6        0.047           
  Mixed                 7                  1.97 (1.54-2.39)   \<0.001              23.1        0.253           

GI: gastrointestinal; HR: hazard ratio; 95% CI: 95% confidence interval; UVA: univariate analysis; MVA: multivariate analysis; NS: not significant.
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